STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders



Status:Archived
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:March 2009
End Date:February 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies


The purpose of this study is to characterize the safety and efficacy of STA-9090 in subjects
with hematologic malignancies.



We found this trial at
3
sites
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Memorial Sloan-Kettering Cancer Center - Basking Ridge
136 Mountainview Blvd
Basking Ridge, New Jersey 7920
(908) 542-3000
Memorial Sloan-Kettering Cancer Center - Basking Ridge At Memorial Sloan Kettering Basking Ridge, we offer...
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials